BMSON Header
보건의료전문가가 아닌 경우, 한국BMS Official Site (https://www.bms.com/kr)을 방문해 주세요.
Log Out My Profile Contact Us

Efficacy of Nivolumab plus Ipilimumab According to Number of IMDC Risk Factors in CheckMate 214

Efficacy of Nivolumab plus Ipilimumab According to Number of IMDC Risk Factors in CheckMate 214

Oct 26, 2021

Error
Error
Success
Success
foot note heading
BMSON Footer